Myth Check · August 9, 2026 · 4 min · By Hector Lindelof
Myth Check: Clear Margins After Mohs Mean the Cancer Cannot Come Back
Mohs surgery offers the most complete margin evaluation available, yet recurrence is not zero. Here is what clear margins actually verify, where the residual risk comes from, and what surveillance is really guarding against.
Patients often leave a Mohs procedure with a reasonable-sounding takeaway: the surgeon checked every edge under the microscope, the margins came back clear, therefore the cancer is gone for good. That summary is close to true, and for most people it will hold. But it flattens some important biology. Clear margins after Mohs mean the tumor was not detectable at the surgical edges of the tissue that was removed. That is a powerful statement, and it is not quite the same as a guarantee.
What Mohs margins actually verify
Standard excision is typically evaluated with what pathologists call bread-loaf sectioning: the specimen is sliced at intervals, and the slices are examined. Depending on how far apart the slices fall, this method visualizes roughly one to two percent of the true margin surface. Mohs uses horizontal frozen sections oriented so that the entire peripheral and deep margin is mounted and read. In principle, close to one hundred percent of the cut surface is examined. That is the mechanistic reason Mohs achieves five-year cure rates around ninety-nine percent for primary basal cell carcinoma and roughly ninety-four to ninety-six percent for recurrent tumors, figures that consistently outperform standard excision for high-risk sites.
Notice, though, what those numbers imply. Ninety-nine percent is not one hundred. A small residual risk survives even complete margin control, and it comes from several identifiable sources rather than from carelessness.
Source one: discontinuous tumor growth
Some tumors do not grow as a single connected mass. Infiltrative and morpheaform basal cell carcinomas can send out thin strands only a few cells wide. Squamous cell carcinoma with perineural invasion can track along a nerve, and tumor cells may travel along that nerve in a pattern called skip lesions, where a segment of nerve looks clean under the microscope while tumor sits farther along it, beyond the excised tissue. If the examined margin passes through one of those clean gaps, the slide is genuinely negative, yet viable tumor remains downstream. This is why perineural invasion, especially of named or large-caliber nerves, often prompts a conversation about adjuvant radiation even after clear Mohs margins.
Source two: the limits of frozen sections
Frozen section histology is very good but not flawless. Freezing introduces artifact. Single atypical cells or tiny tumor nests can be difficult to distinguish from inflammation, scar, or hair follicle structures, particularly in previously treated or heavily sun-damaged skin. Immunostains used during Mohs, such as those that highlight melanocytes in lentigo maligna cases or keratinocytes in poorly differentiated squamous cell carcinoma, narrow this gap considerably, but interpretation still involves judgment at the cellular level. A margin can be read as clear when a handful of tumor cells sit at or just beyond the plane of section.
Source three: field cancerization
This one is frequently misread as recurrence when it is really a new event. Chronically sun-damaged skin carries widespread genetic injury across an entire field, not just at the visible tumor. A patient can have a flawless Mohs result and then develop a new primary cancer a centimeter away two years later. Clinically it can look like the old cancer returned. Biologically it is a separate tumor arising from the same damaged field. Mohs removes a tumor; it does not repair the surrounding skin's mutational burden.
Source four: tumor biology that exceeds surgery
High-risk squamous cell carcinomas, particularly in immunosuppressed patients such as organ transplant recipients, can metastasize to regional lymph nodes even when the primary site is cleared. Margin status at the skin says nothing about cells that departed before surgery. This is why staging systems weigh depth, differentiation, diameter, and perineural invasion, and why some patients are referred for nodal imaging or multidisciplinary review despite clean margins.
What this means in practice
None of this argues against Mohs. It remains the most rigorous margin assessment in skin cancer surgery, and the residual risk after clear margins is small, usually in the low single digits over five years for common tumors. The practical conclusions are narrower and more useful. First, follow-up skin exams are not a formality; most recurrences and most new field cancers appear within the first two to three years, and early detection keeps the next procedure small. Second, if your pathology report mentions perineural invasion, poor differentiation, or deep invasion, additional treatment recommendations after clear margins are not contradictory; they address risk that lives outside the examined tissue. Third, any new firmness, pearly change, or nonhealing spot within or near a scar deserves evaluation, even years later, because scars can conceal early regrowth.
Clear margins are the best surgical evidence available that a tumor is gone. Surveillance is the plan for the small remainder that no microscope can promise away.
Related reading: When Mohs does not clear it: what happens after the fourth stage.
Further reading: Liposomal and Nonliposomal Bupivacaine for Mohs Surgery: A Systematic Review (Dermatol Surg 2024); Artificial Intelligence for Mohs and Dermatologic Surgery: A Systematic Review and Meta-Analysis (Dermatol Surg 2024); 3D bioprinting: a review and potential applications for Mohs micrographic surgery (Arch Dermatol Res 2024).